What is ALS Phase 2 Study KNS-760704?
Category: Others
R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 3 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Why patients stopped taking ALS Phase 2 Study KNS-760704
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Course of treatment ended | 1 |
Duration
Stopped using ALS Phase 2 Study KNS-760704
| Duration | Patients | Percentage |
|---|---|---|
| 6 months - 1 year | 1 |
Last updated: